BRIEF published on 01/27/2026 at 18:05, 1 month 22 days ago Theranexus Liquidity Contract Half-Year Review Liquidity Contract PORTZAMPARC Financial Report Theranexus THX Pharma Actions
BRIEF published on 01/20/2026 at 18:05, 1 month 29 days ago THX Pharma unveils its 2026 financial calendar Euronext Paris Financial Agenda Biopharmaceutical 2026 THX Pharma
BRIEF published on 01/20/2026 at 18:05, 1 month 29 days ago THX Pharma Reveals 2026 Financial Schedule Financial Calendar Neurological Diseases Market Communication 2026 Announcements THX Pharma
PRESS RELEASE published on 01/20/2026 at 18:00, 1 month 29 days ago THX Pharma Announces its 2026 Financial Calendar THX Pharma (Theranexus) announces financial communication agenda for 2026, focusing on rare neurological diseases treatments. Company listed on Euronext Growth Paris Euronext Growth Paris Financial Communication Theranexus Neurological Diseases THX Pharma
BRIEF published on 01/08/2026 at 18:05, 2 months 10 days ago Publication of the letter to shareholders by Theranexus Shareholders Neuroscience Rare Diseases Theranexus Drugs
BRIEF published on 01/08/2026 at 18:05, 2 months 10 days ago THX Pharma Releases Shareholder Letter Drug Development Biopharmaceutical Shareholder Communication Neurological Diseases THX Pharma
PRESS RELEASE published on 01/08/2026 at 18:00, 2 months 10 days ago THX Pharma announces the publication of its letter to shareholders THX Pharma (Theranexus) announces the publication of its letter to shareholders, highlighting treatments for rare neurological diseases and upcoming drug commercialization. Forward-looking statements included Forward-looking Statements Theranexus Neurological Diseases THX Pharma Drug Commercialization
BRIEF published on 01/07/2026 at 08:05, 2 months 12 days ago THX Pharma appoints Julien Veys as Deputy General Manager Business Strategy Appointment THX Pharma Julien Veys Neurological Medications
BRIEF published on 01/07/2026 at 08:05, 2 months 12 days ago THX Pharma Names Julien Veys as Deputy CEO Rare Neurological Diseases THX Pharma Julien Veys Appointment Theranexus Strategy Pharmaceutical Commercialization
PRESS RELEASE published on 01/07/2026 at 08:00, 2 months 12 days ago THX Pharma Announces the Appointment of Julien Veys as Deputy Chief Executive Officer THX Pharma appoints Julien Veys as Deputy CEO to drive new strategy focusing on regulatory approval and commercialization of medicines for rare neurological diseases Regulatory Approval Deputy CEO Neurological Diseases THX Pharma Julien Veys
Published on 03/19/2026 at 07:30, 2 hours ago Tocvan Drone Magnetic Data Strengthens Gold-Silver Targets Across Gran Pilar; Identifies Broad Zones for Expansion Potential
Published on 03/19/2026 at 06:35, 2 hours 55 minutes ago Golden Lake Announces Securityholder Approval of Arrangement with McEwen Inc.
Published on 03/19/2026 at 01:05, 8 hours 25 minutes ago Prospect Ridge Announces Closing of Flow-Through Share Private Placement
Published on 03/18/2026 at 23:45, 9 hours 45 minutes ago Orogen Royalties Announces Private Placement Update
Published on 03/18/2026 at 21:00, 12 hours 30 minutes ago PLDT's Smart Selects Amdocs to Transform Retail Operations with AI-Powered Store Genie
Published on 03/19/2026 at 09:14, 16 minutes ago With JODY-W6, u-blox brings secure tri-band Wi-Fi™6E for industrial IoT
Published on 03/19/2026 at 09:05, 24 minutes ago Huawei announces expansion of Curve Pay contactless payments across HUAWEI WATCH devices
Published on 03/19/2026 at 09:05, 25 minutes ago “Lead Transformation – Generate Impact”: Lenzing Presents Its 2025 Annual and Sustainability Report
Published on 03/19/2026 at 09:01, 28 minutes ago Original-Research: Semperit AG Holding (von NuWays AG): BUY
Published on 03/19/2026 at 08:45, 45 minutes ago Deezer and Sonos renew and expand long-term collaboration
Published on 03/19/2026 at 07:00, 2 hours 30 minutes ago bioMérieux Receives IVDR CE‑Marking for Two BIOFIRE® SPOTFIRE® Panels to Strengthen Near‑Patient Respiratory and Sore Throat Diagnostics Across Europe
Published on 03/19/2026 at 07:00, 2 hours 30 minutes ago 2025 Annual results and new strategic signature
Published on 03/18/2026 at 19:41, 13 hours 48 minutes ago Covivio - Conditions of availability of the 2025 Universal Registration Document
Published on 03/18/2026 at 18:00, 15 hours 30 minutes ago Deezer achieves profitability in FY25 as strategy delivers tangible results
